Gerald T Keusch

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9662826/publications.pdf

Version: 2024-02-01

106 papers	5,556 citations	109137 35 h-index	85405 71 g-index
107 all docs	107 docs citations	107 times ranked	4756 citing authors

#	Article	IF	Citations
1	Infectious Disease Threats: A Rebound To Resilience. Health Affairs, 2021, 40, 204-211.	2.5	50
2	Urgent lessons from COVID 19: why the world needs a standing, coordinated system and sustainable financing for global research and development. Lancet, The, 2021, 397, 1229-1236.	6.3	54
3	Should global financing be the main priority for pandemic preparedness? â€“ Authors' reply. Lancet, The, 2021, 398, 388-389.	6.3	0
4	Science, not speculation, is essential to determine how SARS-CoV-2 reached humans. Lancet, The, 2021, 398, 209-211.	6.3	18
5	An appeal for an objective, open, and transparent scientific debate about the origin of SARS-CoV-2 â€“ Authors' reply. Lancet, The, 2021, 398, 1404-1405.	6.3	0
6	The Origin of COVID-19 and Why It Matters. American Journal of Tropical Medicine and Hygiene, 2020, 103, 955-959.	0.6	134
7	Ethics of randomized trials in a public health emergency. PLoS Neglected Tropical Diseases, 2018, 12, e0006313.	1.3	12
8	Clinical trials during epidemics. Lancet, The, 2017, 389, 2455-2457.	6.3	14
9	Vitamin A deficiency: slow progress towards elimination. The Lancet Global Health, 2015, 3, e502-e503.	2.9	14
10	Environmental Enteric Dysfunction: Pathogenesis, Diagnosis, and Clinical Consequences. Clinical Infectious Diseases, 2014, 59, S207-S212.	2.9	224
11	Perspectives in Foodborne Illness. Infectious Disease Clinics of North America, 2013, 27, 501-515.	1.9	3
12	Implications of Acquired Environmental Enteric Dysfunction for Growth and Stunting in Infants and Children Living in Low- and Middle-Income Countries. Food and Nutrition Bulletin, 2013, 34, 357-364.	0.5	146
13	Sublingually administered Bacillus subtilis cells expressing tetanus toxin C fragment induce protective systemic and mucosal antibodies against tetanus toxin in mice. Vaccine, 2011, 29, 4778-4784.	1.7	31
14	Zoonoses and marginalised infectious diseases of poverty: Where do we stand?. Parasites and Vectors, 2011, 4, 106.	1.0	122
15	The Global Health System: Lessons for a Stronger Institutional Framework. PLoS Medicine, 2010, 7, e1000193.	3.9	77
16	The Global Health System: Actors, Norms, and Expectations in Transition. PLoS Medicine, 2010, 7, e1000183.	3.9	64
17	The Global Health System: Linking Knowledge with Actionâ€”Learning from Malaria. PLoS Medicine, 2010, 7, e1000179.	3.9	26
18	Development of a Bacillus subtilis -Based Rotavirus Vaccine. Vaccine Journal, 2010, 17, 1647-1655.	3.2	44

#	Article	IF	Citations
19	Efficacy, heat stability and safety of intranasally administered Bacillus subtilis spore or vegetative cell vaccines expressing tetanus toxin fragment C. Vaccine, 2010, 28, 6658-6665.	1.7	26
20	Nutritional Implications of Parasitic Infections. Nutrition Reviews, 2009, 39, 149-161.	2.6	35
21	The Potential Impact of Nutritional Change on the Global Burden of Viral Disease. Nutrition Reviews, 2009, 58, S55-S62.	2.6	1
22	Shigellosis. , 2009, , 699-724.		5
23	New challenges in studying nutrition-disease interactions in the developing world. Journal of Clinical Investigation, 2008, 118, 1322-1329.	3.9	66
24	Stigma and global health: developing a research agenda. Lancet, The, 2006, 367, 525-527.	6.3	131
25	Stigma and global health: looking forward. Lancet, The, 2006, 367, 538-539.	6.3	15
26	What do -omics mean for the science and policy of the nutritional sciences?. American Journal of Clinical Nutrition, 2006, 83, 520S-522S.	2.2	24
27	Health Innovation Networks to Help Developing Countries Address Neglected Diseases. Science, 2005, 309, 401-404.	6.0	168
28	Take HEED--if not now, when?. Environmental Health Perspectives, 2004, 112, A144-5.	2.8	0
29	Editorial Commentary: Global Health, Personal Action. Clinical Infectious Diseases, 2004, 38, 879-880.	2.9	0
30	Vitamin E and Respiratory Tract Infections in Elderly Nursing Home Residents. JAMA - Journal of the American Medical Association, 2004, 292, 828.	3.8	263
31	Spreading effective AIDS care in poor countries. A commentary on the Partners-in-Health/Zanmi Lasante experience in Haiti.. Journal of Public Health Policy, 2004, 25, 159-161.	1.0	2
32	THE MULTILATERAL INITIATIVE ON MALARIA: PAST, PRESENT, AND FUTURE. American Journal of Tropical Medicine and Hygiene, 2004, 71, 279-282.	0.6	8
33	The multilateral initiative on malaria: past, present, and future. American Journal of Tropical Medicine and Hygiene, 2004, 71, 279-82.	0.6	2
34	Tapping the power of small institutions. Nature, 2003, 422, 561-562.	13.7	15
35	A Monkey Model for EnterohemorrhagicEscherichia coliInfection. Journal of Infectious Diseases, 2001, 184, 206-210.	1.9	30
36	Shiga Toxins. , 2000, 145, 41-63.		6

#	Article	IF	Citations
37	Mediation of Cryptosporidium parvum Infection In Vitro by Mucin-Like Glycoproteins Defined by a Neutralizing Monoclonal Antibody. Infection and Immunity, 2000, 68, 5167-5175.	1.0	117
38	Quinolone Antibiotics Induce Shiga Toxinâ€“Encoding Bacteriophages, Toxin Production, and Death in Mice. Journal of Infectious Diseases, 2000, 181, 664-670.	1.9	530
39	Clinical Issues. , 2000, , 181-194.		2
40	Shiga Toxins 1 and 2 Translocate Differently across Polarized Intestinal Epithelial Cells. Infection and Immunity, 1999, 67, 6670-6677.	1.0	89
41	Shigellosis. , 1998, , 631-656.		9
42	The Rediscovery of Shiga Toxin and Its Role in Clinical Disease. Japanese Journal of Medical Science and Biology, 1998, 51, S5-S22.	0.4	5
43	In Vivo Transduction with Shiga Toxin 1-Encoding Phage. Infection and Immunity, 1998, 66, 4496-4498.	1.0	6
44	Attachment of Cryptosporidium parvum Sporozoites to Human Intestinal Epithelial Cells. Infection and Immunity, 1998, 66, 3429-3432.	1.0	50
45	In Vivo Transduction with Shiga Toxin 1-Encoding Phage. Infection and Immunity, 1998, 66, 4496-4498.	1.0	136
46	A Vaccine against Rotavirus â€" When is Too Much Too Much?. New England Journal of Medicine, 1997, 337, 1228-1229.	13.9	28
47	Malnutrition and AIDS in the Developing World. Journal of Nutritional Immunology, 1997, 5, 45-50.	0.1	0
48	Detection of Shiga-Like Toxin-Producing Escherichia coli in Ground Beef and Milk by Commercial Enzyme Immunoassay. Journal of Food Protection, 1996, 59, 344-349.	0.8	27
49	Fecal Excretion of Leukotriene C4 during Human Disease Due to Shigella dysenteriae. Journal of Pediatric Gastroenterology and Nutrition, 1995, 20, 179-183.	0.9	3
50	Stimulation of gastrointestinal antibody to Shiga toxin by orogastric immunization in mice. Immunology and Cell Biology, 1994, 72, 69-74.	1.0	5
51	Prevalence of enteric viruses among hospital patients with AIDS in Kinshasa, Zaire. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1993, 87, 263-266.	0.7	25
52	One step high yield affinity purification of shiga-like toxin II variants and quantitation using enzyme linked immunosorbent assays. Microbial Pathogenesis, 1993, 14, 57-66.	1.3	45
53	A Prospective Study of Diarrhea and HIV-1 Infection among 429 Zairian Infants. New England Journal of Medicine, 1993, 329, 1696-1702.	13.9	151
54	Antioxidants in Infection. Journal of Nutritional Science and Vitaminology, 1993, 39, S23-S33.	0.2	10

#	Article	IF	Citations
55	Identification and Partial Purification of a Lectin on the Surface of the Sporozoite of Cryptosporidium parvum. Journal of Parasitology, 1992, 78, 886.	0.3	34
56	Crystallization of the B chain of Shiga-like toxin I from Escherichia coli. Journal of Molecular Biology, 1991, 218, 691-694.	2.0	8
57	In vitro Encystation of Giardia lamblia: Large-Scale Production of In vitro Cysts and Strain and Clone Differences in Encystation Efficiency. Journal of Parasitology, 1991, 77, 974.	0.3	87
58	Nutritional Effects on Response of Children in Developing Countries to Respiratory Tract Pathogens: Implications for Vaccine Development. Clinical Infectious Diseases, 1991, 13, S486-S491.	2.9	35
59	Shiga Toxin: Purification, Structure, and Function. Clinical Infectious Diseases, 1991, 13, S293-S297.	2.9	41
60	Shiga Toxin: Intestinal Cell Receptors and Pathophysiology of Enterotoxic Effects. Clinical Infectious Diseases, 1991, 13, S304-S310.	2.9	34
61	Shigellosis. , 1991, , 593-620.		13
62	Molecular Pathogenesis of Giardia lamblia: Adherence and Encystation. , 1991, , 237-247.		1
63	Micronutrients and Susceptibility to Infection. Annals of the New York Academy of Sciences, 1990, 587, 181-188.	1.8	35
64	A comparison of HEp-2 cell invasion by enteropathogenic and enteroinvasiveEscherichia coli. FEMS Microbiology Letters, 1990, 69, 83-86.	0.7	65
65	Induction of a phosphomannosyl binding lectin activity inGiardia. BioEssays, 1990, 12, 211-215.	1.2	22
66	Vitamin A Supplements â€" Too Good Not to Be True. New England Journal of Medicine, 1990, 323, 985-987.	13.9	29
67	Shigellosis. Pediatric Infectious Disease Journal, 1989, 8, 713-719.	1.1	46
68	Quantitation of the rabbit intestinal glycolipid receptor for Shiga toxin. Gastroenterology, 1989, 97, 384-391.	0.6	38
69	[22] Shiga toxin: Production and purification. Methods in Enzymology, 1988, 165, 152-162.	0.4	28
70	Antimicrobial Therapy for Enteric Infections and Typhoid Fever. Clinical Infectious Diseases, 1988, 10, S199-S205.	2.9	33
71	[33] Shiga toxin as inhibitor of protein synthesis. Methods in Enzymology, 1988, 165, 231-235.	0.4	10
72	Effects of Nutritional Recuperation on E-Rosetting Lymphocytes and in Vitro Response to Thymosin in Malnourished Children. Journal of Pediatric Gastroenterology and Nutrition, 1987, 6, 387-391.	0.9	7

#	Article	IF	Citations
73	Immature Circulating Lymphocytes In Severely Malnourished Guatemalan Children. Journal of Pediatric Gastroenterology and Nutrition, 1987, 6, 265-270.	0.9	14
74	Identification and characterization of taglin, a mannose 6-phosphate binding, trypsin-activated lectin from Giardia lamblia. Biochemistry, 1987, 26, 8669-8675.	1.2	74
75	Selective Primary Health Care: Strategies for Control of Disease in the Developing World. XXIII. Control of Infection to Reduce the Prevalence of Infantile and Childhood Malnutrition. Clinical Infectious Diseases, 1986, 8, 273-287.	2.9	31
76	Shigella Toxin and the Pathogenesis of Shigellosis. Novartis Foundation Symposium, 1985, 112, 193-214.	1.2	21
77	Growth of toxigenic Escherichia coli in Oral Rehydration Solutions. Diagnostic Microbiology and Infectious Disease, 1984, 2, 139-143.	0.8	2
78	Primary amines and chloroquine inhibit cytotoxic responses to Shigella toxin and permit late antibody rescue of toxin treated cells. Biochemical and Biophysical Research Communications, 1984, 121, 69-76.	1.0	20
79	Impairment of hemolytic complement activation by both classical and alternative pathways in serum from patients with kwashiorkor. Journal of Pediatrics, 1984, 105, 434-436.	0.9	13
80	The Epidemiology and Pathophysiology of Invasive Bacterial Diarrheas. , 1983, , 45-72.		3
81	Role of opsonins in clinical response to granulocyte transfusion in granulocytopenic patients. American Journal of Medicine, 1982, 73, 552-563.	0.6	17
82	Infection and diabetes: The case for glucose control. American Journal of Medicine, 1982, 72, 439-450.	0.6	599
83	Co-trimoxazole (Trimethoprim-sulfamethoxazole) An Updated Review of its Antibacterial Activity and Clinical Efficacy. Drugs, 1982, 24, 459-518.	4.9	94
84	Shigellosis. , 1982, , 487-509.		7
85	Shigella toxin(s) : Description and role in diarrhea and dysentery. , 1981, 15, 403-438.		72
86	Host Defense Mechanisms in Protein Energy Malnutrition. , 1981, 135, 183-209.		20
87	RECEPTOR-MEDIATED ENDOCYTOSIS OF SHIGELLA CYTOTOXIN. , 1981, , 95-112.		13
88	Malnutrition and Infection. , 1979, , 307-332.		4
89	Shigella Infections. Clinics in Gastroenterology, 1979, 8, 645-662.	0.6	43
90	Effects of acute endotoxemia and glucose administration on circulating leukocyte populations in normal and diabetic subjects. Metabolism: Clinical and Experimental, 1978, 27, 889-899.	1.5	13

#	Article	IF	Citations
91	Hospital-Acquired Mucormycosis (Rhizopus rhizopodiformis) of Skin and Subcutaneous Tissue. New England Journal of Medicine, 1978, 299, 1115-1118.	13.9	223
92	Combination Amphotericin B-Rifampin Therapy for Pulmonary Aspergillosis in a Leukemic Patient. Chest, 1976, 70, 681-683.	0.4	39
93	Effect of Shigella Enterotoxin on Electrolyte Transport in Rabbit Ileum. Gastroenterology, 1975, 69, 1230-1237.	0.6	40
94	Comparison of Secretory and Histological Effects of Shigella and Cholera Enterotoxins in Rabbit Jejunum. Gastroenterology, 1975, 68, 309-317.	0.6	50
95	Susceptibilities of Gram-Negative Bacteria to Combinations of Antimicrobial Agents In Vitro. Antimicrobial Agents and Chemotherapy, 1975, 8, 164-171.	1.4	14
96	Kinetics of Absorption of Toxin of Vibrio cholerae. Journal of Infectious Diseases, 1975, 131, 210-216.	1.9	7
97	PATHOGENESIS OF SHIGELLA DIARRHEA. III. EFFECTS OF SHIGELLA ENTEROTOXIN IN CELL CULTURE*,â€. Transactions of the New York Academy of Sciences, 1973, 35, 51-58.	0.2	38
98	Group D Streptococcal Bacteremia, with Emphasis on the Incidence and Presentation of Infections Due toStreptococcus bovis. New England Journal of Medicine, 1973, 289, 1400-1403.	13.9	60
99	Extracellular cephalosporinases produced by gram-negative bacilli. Canadian Journal of Microbiology, 1972, 18, 1039-1043.	0.8	2
100	The pathogenesis of Shigella Diarrhea. Journal of Clinical Investigation, 1972, 51, 1212-1218.	3.9	210
101	14 C-Glucose Oxidation in Whole Blood: a Clinical Assay for Phagocyte Dysfunction. Infection and Immunity, 1972, 5, 414-415.	1.0	25
102	Failure of Cholera Enterotoxin to Alter Cyclic 3â€², 5â€²- Adenosine Monophosphate-Mediated Responses in Toad Urinary Bladder. Infection and Immunity, 1972, 5, 634-635.	1.0	2
103	Pathogenesis of Bacterial Diarrheas. New England Journal of Medicine, 1971, 285, 831-841.	13.9	80
104	Biochemical Effects of Cholera Enterotoxin. II. Glucose Metabolism in the Intestine of the Infant Rabbit. Journal of Infectious Diseases, 1971, 124, 188-193.	1.9	10
105	Pathogenesis of Bacterial Diarrheas. New England Journal of Medicine, 1971, 285, 891-900.	13.9	35
106	THE SUSCEPTIBILITY OF BACTEROIDES TO THE PENICILLINS AND CEPHALOTHIN. American Journal of the Medical Sciences, 1966, 251, 428-432,448.	0.4	26